Connect Biopharma Holdings Limited Ordinary Shares (CNTB) Stock
NASDAQ · CNTB
1.28
Fundamentals
Market cap
$80.61M
Price / Earnings ratio
-1.2x
Price / Sales ratio
27.5x
Price / Book ratio
3.0x
Return on assets
-1.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Connect Biopharma Holdings Limited Ordinary Shares
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
SectorHealthcare
IndustryBiotechnology
Employees64
CEODr. Barry David Quart Pharm.D.
IPO DateMar 19, 2021
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Barry David Quart Pharm.D. | CEO & Director | 1957 |
| Mr. David L. Szekeres J.D. | President | 1974 |
| Ms. Lisa Peraza CPA | Senior Vice President of Finance | 1977 |
| Mr. Jeff Cohn J.D. | General Counsel & Corporate Secretary | 1982 |
| Mr. Sean T. Ristine | Vice President of Human Resources | 1970 |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC | 1964 |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) | — |
| Ms. Kimberly J. Manhard | Executive VP & Chief Development Officer | 1960 |
Fundamentals
Valuation
Market cap$80.61M
Price-to-sales ratio27.50
Price-to-book value3.02
Price-earnings ratio-1.20
Return on Equity-122.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.19
Income Statement
Average volume1,768,021
EBITDA$-63.72M
1 year high (52w)$3.82
1 year low (52w)$1.06
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



